Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defining HIV-1 protease substrate selectivity.

Zachary Q Beck1, Garrett M Morris, John H Elder

  • 1Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.

Current Drug Targets. Infectious Disorders
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Narrowing the gap between machine learning scoring functions and free energy perturbation using augmented data.

Communications chemistry·2025
Same author

Sort & Slice: a simple and superior alternative to hash-based folding for extended-connectivity fingerprints.

Journal of cheminformatics·2024
Same author

It is theoretically possible to avoid misfolding into non-covalent lasso entanglements using small molecule drugs.

PLoS computational biology·2024
Same author

PoseBusters: AI-based docking methods fail to generate physically valid poses or generalise to novel sequences.

Chemical science·2024
Same author

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Science (New York, N.Y.)·2023
Same author

Discovery and pharmacophoric characterization of chemokine network inhibitors using phage-display, saturation mutagenesis and computational modelling.

Nature communications·2023
Same journal

Discoveries of Tat-TAR interaction inhibitors for HIV-1.

Current drug targets. Infectious disorders·2006
Same journal

Chemosensitizers in drug transport mechanisms involved in protozoan resistance.

Current drug targets. Infectious disorders·2006
Same journal

Neuraminidase inhibitors as antiviral agents.

Current drug targets. Infectious disorders·2006
Same journal

Developments in antiviral drug design, discovery and development in 2004.

Current drug targets. Infectious disorders·2006
Same journal

Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Current drug targets. Infectious disorders·2005
Same journal

The molecular basis for the mode of action of bicyclomycin.

Current drug targets. Infectious disorders·2005
See all related articles

The HIV-1 aspartyl protease is a key drug target. Understanding its substrate and inhibitor specificity is crucial for developing new drugs to combat viral resistance and improve HIV treatment.

Area of Science:

  • Biochemistry
  • Virology
  • Drug Discovery

Background:

  • The aspartyl protease of Human Immunodeficiency Virus type 1 (HIV-1) is a critical target for antiviral drug development.
  • Highly Active Anti-Retroviral Therapy (HAART), including protease and reverse transcriptase inhibitors, has significantly improved patient outcomes.
  • Drug resistance remains a major challenge, necessitating the development of novel therapeutic strategies and drugs.

Purpose of the Study:

  • To elucidate the molecular basis of substrate and inhibitor specificity for the HIV-1 aspartyl protease.
  • To understand the mechanisms by which drug-resistant HIV-1 mutants evade current therapies.
  • To identify optimal templates for developing broad-spectrum HIV-1 inhibitors.

Main Methods:

  • Characterization of the HIV-1 protease structure.

Related Experiment Videos

  • Analysis of substrate diversity and cleavage mechanisms.
  • Exploration of approaches to define substrate diversity for inhibitor design.

    • Main Results:

    • Detailed insights into the structural characteristics of the HIV-1 protease.
    • Understanding of the known substrate diversity and cleavage mechanisms.
    • Identification of strategies for defining substrate diversity to guide inhibitor development.

    Conclusions:

    • A comprehensive understanding of HIV-1 protease specificity is vital for designing effective inhibitors against resistant strains.
    • Defining substrate diversity aids in the rational design of novel antiviral drugs with broad-spectrum activity.
    • Continued research into protease-substrate interactions is essential for advancing HIV therapy.